The proportion of patients with mean potassium < @ mEq/L during days @-@ was significantly higher in all zirconium cyclosilicate groups vs placebo ( @/@ -LSB- @ % -RSB- , @/@ -LSB- @ % -RSB- , and @/@ -LSB- @ % -RSB- for the @-g , @-g , and @-g groups , vs @/@ -LSB- @ % -RSB- with placebo ; P < @ for each dose vs placebo ) .